Corticosteroid use and risk of XXXX : a population-based case-control study in Denmark.

@entity173 @entity617 @entity565
OBJECTIVE: To examine the association between cumulative CS dose and risk of @entity173 . DESIGN: Population-based case-control design. SUBJECTS AND METHODS: A total of 6660 subjects with @entity173 and 33,272 age-matched population controls were identified using the County Hospital Discharge Registry in North Jutland County, Denmark and the Danish Central Personal Registry, respectively. Data on redeemed prescriptions for CS within the last 5 years before the index date were retrieved from a population-based prescription database, and recalculated to @entity617 equivalents. Cases and controls were categorized according to cumulative CS dose: (i) no use; (ii) <130 mg (e.g. equivalent to 30 mg of @entity617 for 4 days given for an acute exacerbation of @entity565 ); (iii) 130-499 mg (e.g. equivalent to a short course of @entity617 of 450 mg for acute @entity565 ); (iv) 500-1499 mg (e.g. equivalent to 7.5 mg @entity617 daily for 6 months or 800 microg day(-1) of inhaled budesonide for 1 year); and (v) > or =1500 mg (e.g. equivalent to >4.1 mg day(-1) for 1 year, a long-term high dose). Data were analysed using conditional logistic regression adjusted for potential confounders including gender, redeemed prescriptions for hormone replacement therapy, antiosteoporotic, anxiolytic, antipsychotic and antidepressant drugs. RESULTS: Compared with never users, an increased risk of @entity173 was found for CS users, with increasing cumulative doses of any type of CS use during the preceding 5 years [adjusted odds ratio (OR)=0.96, 95% confidence interval (CI)=0.89-1.04] for <130 mg @entity617 ; OR=1.17 (CI=1.01-1.35) for 130-499 mg; OR=1.36 (CI=1.19-1.56) for 500-1499 mg; and OR=1.65 (CI=1.43-1.92) for > or =1500 mg. An increased risk was also found when the study population was stratified according to gender, age and type of CS (systemic or topical). CONCLUSIONS: Even a limited daily dose of CS (more than an average dose of approximately 71 microg @entity617 per day) was associated with an increased risk of @entity173 .
